CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of CVRx, Inc. (NASDAQ:CVRX - Get Free Report) have been given an average rating of "Moderate Buy" by the six brokerages that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $16.60.

A number of research firms have recently weighed in on CVRX. Craig Hallum began coverage on shares of CVRx in a research report on Wednesday. They set a "buy" rating and a $23.00 target price for the company. JPMorgan Chase & Co. downgraded shares of CVRx from an "overweight" rating to a "neutral" rating and reduced their target price for the company from $36.00 to $13.00 in a research report on Wednesday. Lake Street Capital reduced their target price on shares of CVRx from $35.00 to $18.00 and set a "buy" rating for the company in a research report on Wednesday. Canaccord Genuity Group reduced their target price on shares of CVRx from $32.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday. Finally, William Blair downgraded shares of CVRx from an "outperform" rating to a "market perform" rating in a research report on Wednesday.

Insider Activity at CVRx

In related news, major shareholder & Johnson Johnson sold 3,725 shares of CVRx stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other CVRx news, major shareholder & Johnson Johnson sold 3,725 shares of the firm's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares of the company's stock, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Paul Verrastro sold 2,545 shares of the firm's stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $21.91, for a total transaction of $55,760.95. Following the completion of the transaction, the insider now directly owns 2,455 shares of the company's stock, valued at $53,789.05. The disclosure for this sale can be found here. 18.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Level Four Advisory Services LLC boosted its holdings in CVRx by 6.8% in the 4th quarter. Level Four Advisory Services LLC now owns 28,885 shares of the company's stock valued at $908,000 after purchasing an additional 1,844 shares during the period. Federated Hermes Inc. bought a new position in CVRx in the 4th quarter valued at $102,000. Emerald Advisers LLC lifted its holdings in shares of CVRx by 1.3% during the 3rd quarter. Emerald Advisers LLC now owns 501,073 shares of the company's stock worth $7,601,000 after acquiring an additional 6,419 shares during the last quarter. Trexquant Investment LP bought a new stake in shares of CVRx during the 4th quarter worth $426,000. Finally, Jump Financial LLC bought a new stake in shares of CVRx during the 4th quarter worth $499,000. 75.27% of the stock is owned by institutional investors.

CVRx Stock Down 34.8 %

CVRX stock traded down $5.39 during trading on Wednesday, reaching $10.12. The stock had a trading volume of 1,582,348 shares, compared to its average volume of 161,831. CVRx has a one year low of $7.77 and a one year high of $33.13. The company's 50 day moving average is $18.62 and its two-hundred day moving average is $21.07. The company has a market capitalization of $218.54 million, a price-to-earnings ratio of -5.11 and a beta of 1.29. The company has a quick ratio of 12.86, a current ratio of 14.25 and a debt-to-equity ratio of 0.38.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.